IBEX Ltd Chief Sales and CS Officer Bruce Neil Dawson reported two open-market sales of Common Shares. On May 11, 2026, he sold 3,129 shares at a weighted average price of $32.8038 per share. On May 12, 2026, he sold 15,260 shares at a weighted average price of $31.1156. After these transactions, he directly owns 61,895 Common Shares.
IBEX Ltd reports a proposed sale of 14,523 shares of Common Stock tied to the vesting of a PSU grant on 09/30/2025. The filing lists this sale under equity compensation and notes recent open-market dispositions by Robert Thomas Dechant of 6,000 shares on each of several dates in February 2026.
The notice identifies J.P. Morgan Securities LLC as the broker and classifies the shares as Common Stock to be sold on Nasdaq. The filing is a routine regulatory notice of intended resale following equity compensation vesting.
IBEX Ltd filed a Form 144 reporting a proposed resale of 15,260 shares of Common Stock. The filing references a PSU Grant by Issuer with a PSU vest date of 02/06/2026. The notice also lists prior sales of 3,129 shares on 05/11/2026.
The filing is a Form 144 notice related to proposed sales of Common Stock for IBEX. The excerpt lists broker/dealer Wells Fargo Clearing Services and shows transaction-related figures including 3,129, 102,477.50, and 13,389,116 with a date of 05/11/2026. The excerpt also records two issuer RSU vesting entries dated 10/02/2025 (2,269 shares) and 07/01/2025 (860 shares).
IBEX Limited delivered strong growth for the quarter ended March 31, 2026. Revenue reached $164.4 million, up 16.8% from the prior-year quarter, driven by HealthTech, Retail & E-commerce, Travel, Technology and Other verticals, partly offset by lower Telecommunications revenue.
Net income rose to $13.3 million, a 27.3% increase, with diluted earnings per share climbing to $0.89 from $0.73. For the nine-month period, revenue grew 16.7% to $479.8 million, while net income increased 37.8% to $37.6 million and diluted EPS improved to $2.54. Margin gains were helped by higher contributions from offshore delivery centers and growth in higher-margin digital acquisition services, while the company continued investing in AI-enabled CX solutions and new capacity offshore.
IBEX Limited reported strong results for its third fiscal quarter ended March 31, 2026 and raised full-year guidance. Revenue rose 16.8% to $164.4 million, driven by double-digit growth across HealthTech, Technology, Travel & Logistics, and Retail & E-commerce.
Net income increased to $13.3 million, with diluted EPS up 21.9% to $0.89. Adjusted EBITDA grew to $22.0 million, while free cash flow improved to $6.6 million. The company now expects fiscal 2026 revenue of $638–$642 million and adjusted EBITDA of $82–$84 million, and highlighted a new strategic AI partnership with Sierra.ai.
IBEX Limited Schedule 13G shows American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute for Medical Research report beneficial ownership of 680,774 shares of IBEX common stock (CUSIP G4690M101 representing 5.1% of the class). The filing lists sole voting power of 673,665 shares and sole dispositive power of 680,774. The registrants state ACIM is an investment adviser and ACIM/ACC/Stowers jointly consented to the filing.
IBEX Ltd director Daniella Ballou-Aares reported selling 6,500 Common Shares in open-market transactions and now holds 10,643 shares directly. The sales included 5,843 shares at $24.2175 and 157 shares at $24.2114 on March 13, 2025, plus 500 shares at $35.01 on December 2, 2025.
Jones John William reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director John William Jones received an equity award of 2,250 common shares through restricted stock units. The RSUs carry a right to one common share each at no cash cost. The award vests 25% on July 1, 2026 and 25% annually for three additional years, contingent on his continued service. Following this grant, his direct ownership totals 15,244 common shares.
IBEX Ltd director Zhuang Mingzhe acquired 2,083 common shares through a stock award. The Form 4 shows a grant of restricted stock units (RSUs) at a price of $0.00 per share, increasing his direct holdings to 7,083 common shares.
The RSUs vest over four years. Twenty‑five percent vest on July 1, 2026, with an additional 25% vesting on each of the next three anniversaries, as long as he remains in continuous service on each vesting date.